

Media Release

Zug, 25 March 2026

Merck, Sharp & Dohme to Acquire HBM Portfolio Company Terns Pharmaceuticals for USD 6.7 Billion

HBM Healthcare Investments, a healthcare-focused investment company, today announced that its publicly listed portfolio company, Terns Pharmaceuticals (Nasdaq: TERN), will be acquired by Merck Sharp & Dohme (“MSD”) (NYSE: MRK) for USD 53.00 per share in cash.

HBM Healthcare Investments began building a position in Terns Pharmaceuticals in February 2024 and invested a total of USD 19 million in the company over time. MSD’s acquisition now returns approximately three times the capital invested.

The takeover of Terns Pharmaceuticals marks the seventh acquisition from the HBM portfolio in the current financial year - following Merus, Y-mAbs Therapeutics, 89Bio, Akeru, Bluejay Therapeutics, and Swixx Biopharma - and underscores both the strength of our investment strategy and the growing demand among pharmaceutical companies for innovative new therapies.

Terns Pharmaceuticals is a clinical-stage oncology company developing high-impact, transformative medicines by redefining established biological pathways. Its lead program, TERN-701, is a highly selective, oral, allosteric BCR::ABL1 inhibitor with a potentially best-in-class profile, offering the potential for meaningful improvements in efficacy, safety, and convenience for patients with chronic myeloid leukemia.

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or via e-mail at andreas.wicki@hbmhealthcare.com.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. 08/20285